Methotrexate-Ebeve concentrate 500mg/5ml 5 ml

Antitumor drug from the group of antimetabolites – analogues of folic acid. Along with antitumor it has immunosuppressive effect. It inhibits dihydrofolate reductase, which is involved in the reduction of dihydrofolic acid to tetrahydrofolic acid – a carrier of carbon fragments required for the synthesis of purine nucleotides and their derivatives. Inhibits DNA synthesis, repair and cellular mitosis (S-phase).

Indications

acute leukemia (especially lymphoblastic and myeloblastic variants);

Pharmacological effect

An antitumor drug from the group of antimetabolites – folic acid analogues. Along with antitumor, it has an immunosuppressive effect. Inhibits dihydrofolate reductase, which is involved in the reduction of dihydrofolic acid to tetrahydrofolic acid – a transporter of carbon fragments necessary for the synthesis of purine nucleotides and their derivatives. Inhibits DNA synthesis, repair and cell mitosis (in S-phase).

Special instructions

The drug Methotrexate-Ebewe is a cytotoxic drug, so care must be taken when handling it. The drug should be prescribed by a doctor who has experience in the use of methotrexate and is familiar with its properties and characteristics of action. Before prescribing methotrexate, you should ensure that it is possible to determine the plasma concentration of the drug. Taking into account the possibility of severe toxic reactions, including death, the doctor is obliged to inform the patient in detail about the possible risk and necessary precautions.

Active ingredient

Methotrexate

Composition

1 bottle contains:

Pregnancy

The use of methotrexate during pregnancy can cause serious malformations of the fetus (increase in the incidence of malformations of the skull, cardiovascular system and limbs by 14 times), therefore the drug Methotrexate-Ebeve is contraindicated during pregnancy.

Contraindications

hypersensitivity to methotrexate and/or any other component of the drug;

Side Effects

According to the World Health Organization (WHO), adverse events are classified according to the frequency of their development as follows: very often (≥1/10), often (from ≥1/100 to Infectious and parasitic diseases often: herpes zoster; uncommon: opportunistic infections, including pneumonia (including fatal); rare: sepsis (including very rarely fatal); very rarely: nocardiosis, histoplasmosis, cryptococcosis, hepatitis and disseminated infections caused by herpes simplex virus, infections caused by cytomegalovirus (including pneumonia); frequency unknown: reactivation of hepatitis B virus, hepatitis C virus.

Interaction

The likelihood of hepatotoxicity from methotrexate increases with regular use of ethanol and concomitant use of other hepatotoxic drugs (for example, azathioprine, leflunomide, sulfasalazine, retinoids).

Overdose

Symptoms: symptoms associated with inhibition of the hematopoietic system are mainly observed.

Recommendations for use

Methotrexate is included in many chemotherapy treatment regimens, and therefore, when choosing the route of administration, regimen and doses in each individual case, one should be guided by data from specialized literature.

Storage conditions

In a place protected from light at a temperature of 15-25 ° C.
Keep out of the reach of children!

Shelf life

3 years

Manufacturer

Ebewe Pharma, Austria